*Read Disclaimer Sponsored Content
{{current_date_full}} | Unsubscribe
Hello!
New Alert: Vyome Holdings, Inc. (Nasdaq: HIND)
HIND is our brand new NASDAQ under-the-radar alert.
HIND is a newly listed NASDAQ company that just began trading on the exchange in 2025.
The company has a chart setup positioning for a potentially big breakout higher.
Over the past week, HIND has been building what could be a foundation for a substantial rally higher.
In addition, the company has announced multiple developments recently that could serve as big growth catalysts.
HIND is NASDAQ listed “clinical-stage biopharmaceutical company”.
HIND is “focused on developing therapies for serious immuno-inflammatory and rare conditions”.
HIND is creating a “3-pillar healthcare platform at the intersection of biotech, medical devices, and AI in healthcare”.
“Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions.”
HIND is “building the world’s premier platform spanning the US-India innovation corridor”.
By applying groundbreaking science and its unique positioning, HIND “seeks to deliver lasting value to shareholders in a cost-efficient manner while upholding global standards of quality and safety”.
HIND has “invested millions of dollars to build a portfolio of immuno-inflammatory assets rooted in strong mechanistic science”.
Today, the company is focused on “delivering results, with multiple programs advancing toward 12–24 month catalysts that have the potential to create meaningful impact for patients and value for stakeholders”.
HIND is advancing treatments in areas of urgent need and low innovation.
Immuno-inflammatory diseases alone “represent a $120B+ market growing rapidly”.
Patients with rare or resistant conditions are still underserved.
Here is a look at the company’s pipeline:
1. Malignant Fungating Wounds (MFW) – “Bringing dignity back to late-stage cancer care”
“VT1953 is the first targeted therapy for MFW. Reducing odor, pain, and inflammation through a dual mechanism.”
“VT-1953 topical gel is designed to treat the symptoms of MFW by targeting the cause of malodor and inhibiting the drivers of inflammation.”
“Interim Phase 2 Investigator-Initiated Study data demonstrated statistically significant reductions in malodor (P<0.001) — the primary endpoint”
“Patients also reported reductions in pain and improvements in quality of life”
“VT-1953 continues to show an excellent safety profile”
“FDA discussions on pivotal study design and Orphan drug designation are planned for the first half of 2026”
MFW is a debilitating condition that “occurs in 5-14% of advanced cancer patients” where “cancer cells break through the skin and cause a chronic wound (MFW), which is extremely distressing to patients, given the high burden of symptoms.”
Sadly, “It is estimated that there are over 693,000 patients with advanced cancer in the US alone and approximately 10M globally.”
2. Uveitis – “A safer and steroid sparing path for Uvetis”
“VT1908, our non-steroidal eye drop, matches steroid performance in preclinical models—without the risks.”
Uveitis is the inflammation of a part of the eye, and is “implicated in 30,000 new cases of legal blindness annually, in the United States alone”.
“Steroids are the first line of treatment for uveitis, but many patients do not respond, and steroid use causes major complications, including cataract and increased pressure in the eye, leading to glaucoma.”
“There is a huge unmet need for a topically administered drug to replace steroid use in the eye.”
The company has announced multiple accomplishments since it began trading on the NASDAQ in August.
In September, the company announced:
“Vyome Holdings Acquires MIT AI Spinout Oculo Health”
"The goal is to establish an entirely new therapeutic category at the intersection of mental health, psychoneuroimmunology, and digital health, with global commercialization beginning in the US and India. The team at Oculo has developed an innovative foundation of software and research, including on biomarkers such as ‘brain burn’ that are quite relevant to our focus at Vyome, and we are excited to build on this foundation," added Pomichter.
In addition:
"The market size for digital therapeutics, especially ones that can reduce the reliance on biologics or other drugs, could end up being greater than $100B over the next decade," said Mohanjit Jolly, a Director at Vyome and Partner at Iron Pillar, a firm with several AI related investments in the US and India. "The advances in AI create an opportunity to use data to better human lives across the board, but our focus is on reducing inflammation in every part of the body. It is one of the biggest health issues facing our society and leads to significant reliance on harmful drugs. I’m excited we were able to close this transaction with Oculo to launch our AI efforts in addition to advancing our existing inflammation-focused biotech assets."
In November, the company announced:
“Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing”
Here are some of the company’s comments from this press release:
"Vyome is targeting one of the biggest challenges in the world today - inflammation. So many of our medical and mental problems are linked to increased inflammation. We are building our business with a laser focus on shareholder value, whether it’s our capital structure, the development of our assets, or looking at AI opportunities," said Krishna Gupta, Chairman of Vyome. "We had a great first quarter as a public company thanks to our unique strengths, including expertise in/access to the US-India innovation corridor. We announced an important interim result for our drug targeting the billion-dollar opportunity in malignant fungating wound (MFW), and it’s just the beginning!"
In addition:
"This quarter marks a defining step forward for Vyome. We executed a highly efficient transition to the public markets, spending less cash than expected in our first quarter as a public company and strengthening our organization while advancing our lead program," noted Venkat Nelabhotla, CEO of Vyome. He further added, "The promising interim Phase 2 results for VT-1953 reinforce the scientific promise of our immuno-inflammation platform. With our disciplined operations, clean capital structure, and world-class team, we are well-positioned to deliver on the milestones ahead and drive long-term value for both shareholders and patients."
In December, the company announced:
“Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval”
Here are the highlights from this press release:
“VT-1953 treatment over 14 days resulted in highly statistically significant improvements in bad smell or malodor associated with malignant fungating wound (primary endpoint) (P = 0.002).”
“Patient-reported impact of bad smell or malodor on quality of life (secondary endpoint) improved significantly (P = 0.0256), as did wound pain reduction (P = 0.002)”
“VT-1953 was well-tolerated, with no new safety concerns observed.”
“Based on these positive Phase 2 results, the company plans to advance VT-1953 into a pivotal study following discussions with the FDA to seek approval to enter $1B potential addressable market opportunity.”
Here are some of the company’s comments from this press release:
“Venkat Nelabhotla, CEO of Vyome, stated that "these positive results reinforce the potential of VT1953, and we are now preparing to engage with the FDA to design and initiate a pivotal Phase III clinical study in 2026. Over the past several months, we have strengthened our team with top-tier clinical, regulatory, and scientific leaders who bring deep experience in advancing differentiated therapies. This positions us well for disciplined execution as we move into the next phase of development. Vyome remains well capitalized through 2026, allowing us to advance VT1953, a potentially orphan designation program, as a part of our broader chronic immune-inflammation portfolio. We look forward to progressing this program thoughtfully and responsibly toward its next key milestones."”
In addition, the company also announced:
“Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company”
“Born from the prestigious MIT Media Lab, Humanyze has one of the world’s largest databases for employee interactions within the workplace and is working to redefine the future of work through science-backed analytics and AI-enabled insights that help large, complex companies make continuous workplace improvements that benefit both employees and the business.”
Here are the comments from this press release:
"One of our immediate objectives as the Board of Directors of Vyome was to find a way to create value from LiveChain, as we promised LiveChain and Vyome shareholders. We evaluated multiple options, but this path is the first step of a plan that could enable LiveChain to become self-sufficient financially and build a scalable independent business that could generate significant value for shareholders," commented Venkat Nelabhotla, Board member of LiveChain and CEO of Vyome. "Humanyze is attacking one of the biggest issues facing Fortune 1000 companies around the world – human capital, and the cost of developing, retaining, and rewarding people in the most cost-effective way possible."
In addition:
"Humanyze has built a compelling AI-enabled platform that breaks down critical data to give employers clear, actionable insights that optimize many companies’ most valuable resource, their human capital. This optimization is even more critical in an age where humans and AI have to waltz together in the workplace. We see multiple ways for Humanyze to monetize their offerings, and the market opportunity is quite compelling," added Krishna Gupta, Chairman of Vyome.
Two weeks ago, the company announced:
“Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study”
Here are the highlights from this press release:
“Third-party analysis estimates the total addressable U.S. market to be approximately USD 2.2 billion”
“Modeled peak annual U.S. sales approaching USD 600 million for VT-1953”
“Independent valuation analysis estimates post-Phase 3 asset value approaching USD 1 billion, and the current valuation with a positive Phase 2 is estimated to be USD 455 million”
Here are some of the comments from this press release:
"Malignant fungating wounds represent one of the most severe and underserved conditions in oncology supportive care," said Tom Filipczak, Managing Director and Partner at Destum Partners. "Our team conducted rigorous primary and secondary research, including clinician interviews, epidemiology modeling, pricing benchmarking, and valuation analyses. Based on the absence of approved therapies and the high unmet need, we believe this indication represents a compelling clinical and commercial opportunity."
Furthermore:
"This independent analysis reinforces our conviction in the potential of VT-1953," said Venkat Nelabhotla, Chief Executive Officer of Vyome. "We engaged a highly experienced third-party consulting firm to conduct a rigorous and unbiased assessment of the commercial opportunity for this program, where there are currently no FDA-approved drugs. Destum Partners’ conclusion around the total addressable market in the U.S., together with the modeled potential peak sales and significant post-Phase 3 potential valuation, provides important external validation as we seek to advance VT-1953 toward pivotal development."
On Monday, the company announced:
“Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results”
“Company Chose Minimal Dilution Path with No Warrants and Has Sufficient Liquidity to Deliver Initial Phase 3 Results for MFW product”
Here are some of the company’s comments from this press release:
"We have always been focused on shareholder value and are extremely pleased to report we have successfully funded our most important project’s estimated costs until interim findings anticipated in mid-2027," commented Krishna Gupta, Chairman of Vyome. "Inflammation is one of the biggest problems facing the world, and symptoms of MFW are our first target, via VT-1953, in immune-inflammation. As we recently disclosed in an independent valuation report, VT-1953 is estimated by a third party to be worth $1 billion upon anticipated completion of the Phase 3 clinical trials in approximately 18 months. To have achieved this funding at relatively minimal dilution – while turning down funding options at much higher dilution – shows our focus on shareholder value."
In addition:
"In the last week, we were aggressively solicited by multiple investment banks offering larger blocks of capital, but with warrants, investor rights, and other strings attached that we believe would have been harmful to our shareholders," added Venkat Nelabhotla, CEO of Vyome. "Instead, we sourced the absolute lowest cost of capital, with no warrants, and we believe that we are now very well-funded to execute on the plan we have previously laid out to the market on getting VT-1953 through the interim results of Phase 3 clinical trials. We look forward to providing additional updates on our progress soon."
HIND could be positioned for a big breakout higher.
Make sure to do your own due diligence.
Happy Trading!
SmallCapStocks Team
Note: We encourage all traders and investors to develop personal trading rules that you can follow and that work for you. Always protect your downside and note that we alert extremely volatile short-term opportunities. Before investing in securities, you should always consult with your financial, tax and legal advisor and never invest money you cannot afford to lose.
DISCLAIMER:
You should read and understand this disclaimer in its entirety before joining the website or email/blog list of SmallCapStocks.com (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.
The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at www.sec.gov; the Financial Industry Regulatory Authority (the "FINRA") at www.FINRA.org, and relevant State Securities Administrator website and the OTC Markets website at www.otcmarkets.com. The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at www.sec.gov/consumer/cyberfr.htm, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.
The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.
Owners and operators of the Publisher expect to be compensated nine thousand dollars by bank wire transfer on 2/6/26 for the distribution of this advertisement about HIND dated 2/6/26. The Publisher and its owners and operators hold no stocks or bonds in companies discussed in the Advertisement. Owners and operators of the Publisher own several newsletters, therefore you may receive multiple publications and emails featuring companies at different or the same time.
You are receiving this report/release because you subscribed to receive it at our website or through a third-party site. All our newsletters include an "unsubscribe" link, and you can remove yourself at any time from our newsletters by clicking on that "unsubscribe" link. You can also contact us at [email protected] to change your information at any time. By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link:
By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.